ATM-3507

SKU: orb1710373

Description

ATM-3507 is a small molecule protomyosin inhibitor with demonstrated anticancer activity. It has been studied in vitro for human melanoma and is a candidate for investigating ovarian cancer mechanisms in cellular and animal models.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1861449-70-8
• MW: 611.79
• Purity: 99.19% (May vary between batches)
• Formula: C₃₇H₄₆FN₅O₂
• SMILES: CN1CCN(CCCn2c(C)c(C)c3cc(Oc4cccc(c4)C(=O)N4CCN(CCc5ccc(F)cc5)CC4)ccc23)CC1
• Target: Myosin
• Solubility: DMSO:20 mg/mL (32.69 mM)

Bioactivity

• Target IC50:
  Tropomyosin (human melanoma cells):3.83-6.84 μM
• In Vivo:
  The maximum tolerated doses (MTD) of TR100 and ATM-3507 were 60 mg/kg and 150 mg/kg, respectively. The study found that twice-weekly intravenous administration of ATM-3507 also demonstrated combination efficacy, and both combination therapies significantly inhibited tumor growth and prolonged animal survival compared to each monotherapy. Median survival increased from 18 days in mice treated with ATM-3507 to more than 49 days in mice treated with the combination therapy. The effect on body weight was minimal with each therapy or combination of therapies. Drug levels were determined after intravenous administration of 30 mg/kg of ATM-3507 to Balb/c mice (n=3 per time point). Steady-state plasma clearance and volume of distribution of ATM-3507 were observed to be 33.8 mL/min/kg and 7.23 L/kg, respectively .The mean half-life of terminal elimination of ATM-3507 was 5.01 hours. The mean AUC0-t in plasma was 14,548 ng/h/mL.
  Read more...
• In Vitro:
  The combination of two troponin inhibitors plus vincristine was completely cytotoxic to CHLA-20 cells. These cell lines differed in the relative expression of Tpm3.1 as well as in the expression of other isoenzymes. All four cell lines showed some degree of synergistic effect as determined by the Chou-Talalay method. This effect was not limited to periwinkle alkaloids, as similar combined efficacy was observed with paclitaxel plus TR100 or ATM-3507 . In determining the IC50 concentrations of TR100 and ATM-3507 (CHLA-20: 4.99 ± 0.45 μM, CHP-134: 3.83 ± 0.67 μM, CHLA-90: 6.84 ± 2.37 μM, SK-N-BE(2): 5.00 ± 0.42 μM : 5.00 ± 0.42 μM) in a neuroblastoma The combination of troponin inhibitors and vincristine was tested in cell lines, and each drug killed less than 50% of neuroblastoma cells when used alone.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ATM 3507, ATM3507, ATM-3507, Myosin, tropomyosin

Compound Identifiers

PubChem CID

118666864